This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Cave, M. C. Articles by McClave, S. A. PubMed PubMed Citation Articles by Cave, M. C. Articles by McClave, S. A. Social Bookmarking                   What's this?

Obesity, Inflammation, and the Potential Application of Pharmaconutrition

Matt C. Cave, MD^*, Ryan T. Hurt, MD^*,, Thomas H. Frazier, MD^*, Paul J. Matheson, PhD, Richard N. Garrison, MD^,||, Craig J. McClain, MD^*,,|| and Stephen A. McClave, MD^*

^* Departments of Medicine, Physiology and Biophysics, Surgery, and Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky; and the^|| Louisville Veterans Affairs Medical Center, Louisville, Kentucky

Correspondence: Stephen A. McClave, MD, Department of Medicine, Division of Gastroenterology/Hepatology, University of Louisville School of Medicine, 500 S. Jackson Street, University of Louisville, Louisville, KY 40292. Electronic mail may be sent to samcclave{at}louisville.edu.

Obesity is an emerging problem worldwide. Hospitalized obese patients often have a worse outcome than patients of normal weight, particularly in the setting of trauma and critical care. Obesity creates a low-grade systemic inflammatory response syndrome (SIRS) that is similar (but on a much smaller scale) to gram-negative sepsis. This process involves up-regulation of systemic immunity, is characterized clinically by insulin resistance and the metabolic syndrome, and puts the patient at increased risk for organ failure, infectious morbidity, and mortality. Through lipotoxicity and cytokine dysregulation, obesity may act to prime the immune system, predisposing to an exaggerated subsequent immune response when a second clinical insult occurs (such as trauma, burns, or myocardial infarction).

Specialized nutrition therapy for such patients currently consists of a hypocaloric, high-protein diet. However, this approach does not address the putative pathophysiologic mechanisms of inflammation and altered metabolism associated with obesity. A number of dietary agents such as arginine, fish oil, and carnitine may correct these problems at the molecular level. Pharmaconutrition formulas may provide exciting innovations for the nutrition therapy of the obese patient.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?